- Home
- MGTX vs STRO Comparison
MGTX vs STRO Comparison
Compare MGTX & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- STRO
- Stock Information
- Founded
- MGTX 2015
- STRO 2003
- Country
- MGTX United States
- STRO United States
- Employees
- MGTX N/A
- STRO N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGTX Health Care
- STRO Health Care
- Exchange
- MGTX Nasdaq
- STRO Nasdaq
- Market Cap
- MGTX 411.4M
- STRO 272.1M
- IPO Year
- MGTX N/A
- STRO 2018
- Fundamental
- Price
- MGTX $5.94
- STRO $3.71
- Analyst Decision
- MGTX Strong Buy
- STRO Strong Buy
- Analyst Count
- MGTX 2
- STRO 8
- Target Price
- MGTX $22.50
- STRO $12.13
- AVG Volume (30 Days)
- MGTX 297.1K
- STRO 575.2K
- Earning Date
- MGTX 11-12-2024
- STRO 11-11-2024
- Dividend Yield
- MGTX N/A
- STRO N/A
- EPS Growth
- MGTX N/A
- STRO N/A
- EPS
- MGTX N/A
- STRO N/A
- Revenue
- MGTX $8,122,000.00
- STRO $169,359,000.00
- Revenue This Year
- MGTX $133.83
- STRO N/A
- Revenue Next Year
- MGTX $655.34
- STRO N/A
- P/E Ratio
- MGTX N/A
- STRO N/A
- Revenue Growth
- MGTX 26.87
- STRO 197.83
- 52 Week Low
- MGTX $3.49
- STRO $2.01
- 52 Week High
- MGTX $7.60
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- MGTX 82.29
- STRO 48.96
- Support Level
- MGTX $3.97
- STRO $3.27
- Resistance Level
- MGTX $6.07
- STRO $3.95
- Average True Range (ATR)
- MGTX 0.31
- STRO 0.19
- MACD
- MGTX 0.21
- STRO 0.05
- Stochastic Oscillator
- MGTX 93.82
- STRO 64.71
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.